Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | HKDC1 | Q2TB90 | 3/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAT2A | P31153 | 1/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
| ▸ | USP14 | P54578 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12722006 | 1.00 | KDM4E (0.41) | KDM4EATML3MBTL1PTGDR2JAK2 | |
| SCHEMBL12722004 | 0.99 | KDM4E (0.40) | KDM4EATML3MBTL1PTGDR2JAK2 | |
| SCHEMBL12721984 | 0.99 | KDM4E (0.40) | KDM4EATML3MBTL1PTGDR2JAK2 | |
| SCHEMBL12722037 | 0.99 | KDM4E (0.39) | KDM4EATML3MBTL1PTGDR2JAK2 | |
| SCHEMBL12721959 | 0.99 | KDM4E (0.42) | KDM4EATML3MBTL1PTGDR2JAK2 | |
| SCHEMBL12722023 | 0.98 | KDM4E (0.38) | KDM4EATML3MBTL1PTGDR2JAK2 | |
| SCHEMBL17461196 | 0.96 | KDM4E (0.44) | KDM4EATML3MBTL1PTGDR2JAK2 | |
| SCHEMBL12231656 | 0.96 | KDM4E (0.44) | KDM4EATML3MBTL1PTGDR2JAK2 | |
| SCHEMBL12721997 | 0.96 | KDM4E (0.38) | KDM4EATML3MBTL1PTGDR2JAK2 | |
| SCHEMBL12722019 | 0.96 | KDM4E (0.38) | KDM4EATML3MBTL1PTGDR2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7927719-B2 | Silanylamine-based compound, method of preparing the same and organic light emitting device including organic layer comprising the silanylamine-based compound | SAMSUNG MOBILE DISPLAY CO., LTD. (KR) | 2011-04-19 | — | — | US | disclosed |
| US-20080106188-A1 | SILANYLAMINE-BASED COMPOUND, METHOD OF PREPARING THE SAME AND ORGANIC LIGHT EMITTING DEVICE INCLUDING ORGANIC LAYER COMPRISING THE SILANYLAMINE-BASED COMPOUND | SAMSUNG DISPLAY CO., LTD. (KR) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080106188-A1 | SILANYLAMINE-BASED COMPOUND, METHOD OF PREPARING THE SAME AND ORGANIC LIGHT EMITTING DEVICE INCLUDING ORGANIC LAYER COMPRISING THE SILANYLAMINE-BASED COMPOUND | ICMT, SLC43A1, SLC7A5 | KDM4E 2673/4885ATM 4190/4885L3MBTL1 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.